Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma

F. Di Filippo, D. Giannarelli, C. Botti, S. Calini, F. Cavaliere, R. Garinei, M. Schiratti, V. Casaldi, M. Tedesco, R. Cavaliere

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Eighty patients with locally advanced, high grade soft tissue sarcoma of the extremities were studied prospectively in order to determine the efficacy of hyperthermic antiblastic perfusion (H.A.P) as the first step of a combined multimodality therapy. All of the patients have been evaluated in terms of functional results, loco-regional control and survival according to the different treatment schedules adopted. The first clinical trial employed H.A.P., followed by surgery alone. Because the results obtained were unsatisfactory, the protocol was modified to include a continuous intra-arterial (i.a.) infusion of doxorubicin (dx) or radiotherapy before surgery. The best results have been obtained with the radiotherapy-including protocol showing a conservative surgery rate of 100% and a 94% rate of loco-regional control. The disease-free, distant disease-free and overall survival rates were 68%, 75% and 70%, respectively. The importance of the treatment protocol has been confirmed in a multivariate analysis which demonstrated that the treatment protocol adopted is one of the prognostic factors with an independent value (p = 0.06).

Original languageEnglish
Pages (from-to)71-74
Number of pages4
JournalAnnals of Oncology
Volume3
Issue numberSUPPL. 2
Publication statusPublished - 1992

Fingerprint

Sarcoma
Extremities
Perfusion
Clinical Protocols
Radiotherapy
Intra Arterial Infusions
Doxorubicin
Disease-Free Survival
Appointments and Schedules
Therapeutics
Multivariate Analysis
Survival Rate
Clinical Trials
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Di Filippo, F., Giannarelli, D., Botti, C., Calini, S., Cavaliere, F., Garinei, R., ... Cavaliere, R. (1992). Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma. Annals of Oncology, 3(SUPPL. 2), 71-74.

Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma. / Di Filippo, F.; Giannarelli, D.; Botti, C.; Calini, S.; Cavaliere, F.; Garinei, R.; Schiratti, M.; Casaldi, V.; Tedesco, M.; Cavaliere, R.

In: Annals of Oncology, Vol. 3, No. SUPPL. 2, 1992, p. 71-74.

Research output: Contribution to journalArticle

Di Filippo, F, Giannarelli, D, Botti, C, Calini, S, Cavaliere, F, Garinei, R, Schiratti, M, Casaldi, V, Tedesco, M & Cavaliere, R 1992, 'Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma', Annals of Oncology, vol. 3, no. SUPPL. 2, pp. 71-74.
Di Filippo F, Giannarelli D, Botti C, Calini S, Cavaliere F, Garinei R et al. Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma. Annals of Oncology. 1992;3(SUPPL. 2):71-74.
Di Filippo, F. ; Giannarelli, D. ; Botti, C. ; Calini, S. ; Cavaliere, F. ; Garinei, R. ; Schiratti, M. ; Casaldi, V. ; Tedesco, M. ; Cavaliere, R. / Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma. In: Annals of Oncology. 1992 ; Vol. 3, No. SUPPL. 2. pp. 71-74.
@article{9d7d01026dfe4d55ba614054a359b078,
title = "Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma",
abstract = "Eighty patients with locally advanced, high grade soft tissue sarcoma of the extremities were studied prospectively in order to determine the efficacy of hyperthermic antiblastic perfusion (H.A.P) as the first step of a combined multimodality therapy. All of the patients have been evaluated in terms of functional results, loco-regional control and survival according to the different treatment schedules adopted. The first clinical trial employed H.A.P., followed by surgery alone. Because the results obtained were unsatisfactory, the protocol was modified to include a continuous intra-arterial (i.a.) infusion of doxorubicin (dx) or radiotherapy before surgery. The best results have been obtained with the radiotherapy-including protocol showing a conservative surgery rate of 100{\%} and a 94{\%} rate of loco-regional control. The disease-free, distant disease-free and overall survival rates were 68{\%}, 75{\%} and 70{\%}, respectively. The importance of the treatment protocol has been confirmed in a multivariate analysis which demonstrated that the treatment protocol adopted is one of the prognostic factors with an independent value (p = 0.06).",
author = "{Di Filippo}, F. and D. Giannarelli and C. Botti and S. Calini and F. Cavaliere and R. Garinei and M. Schiratti and V. Casaldi and M. Tedesco and R. Cavaliere",
year = "1992",
language = "English",
volume = "3",
pages = "71--74",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Hyperthermic antiblastic perfusion for the treatment of soft tissue limb sarcoma

AU - Di Filippo, F.

AU - Giannarelli, D.

AU - Botti, C.

AU - Calini, S.

AU - Cavaliere, F.

AU - Garinei, R.

AU - Schiratti, M.

AU - Casaldi, V.

AU - Tedesco, M.

AU - Cavaliere, R.

PY - 1992

Y1 - 1992

N2 - Eighty patients with locally advanced, high grade soft tissue sarcoma of the extremities were studied prospectively in order to determine the efficacy of hyperthermic antiblastic perfusion (H.A.P) as the first step of a combined multimodality therapy. All of the patients have been evaluated in terms of functional results, loco-regional control and survival according to the different treatment schedules adopted. The first clinical trial employed H.A.P., followed by surgery alone. Because the results obtained were unsatisfactory, the protocol was modified to include a continuous intra-arterial (i.a.) infusion of doxorubicin (dx) or radiotherapy before surgery. The best results have been obtained with the radiotherapy-including protocol showing a conservative surgery rate of 100% and a 94% rate of loco-regional control. The disease-free, distant disease-free and overall survival rates were 68%, 75% and 70%, respectively. The importance of the treatment protocol has been confirmed in a multivariate analysis which demonstrated that the treatment protocol adopted is one of the prognostic factors with an independent value (p = 0.06).

AB - Eighty patients with locally advanced, high grade soft tissue sarcoma of the extremities were studied prospectively in order to determine the efficacy of hyperthermic antiblastic perfusion (H.A.P) as the first step of a combined multimodality therapy. All of the patients have been evaluated in terms of functional results, loco-regional control and survival according to the different treatment schedules adopted. The first clinical trial employed H.A.P., followed by surgery alone. Because the results obtained were unsatisfactory, the protocol was modified to include a continuous intra-arterial (i.a.) infusion of doxorubicin (dx) or radiotherapy before surgery. The best results have been obtained with the radiotherapy-including protocol showing a conservative surgery rate of 100% and a 94% rate of loco-regional control. The disease-free, distant disease-free and overall survival rates were 68%, 75% and 70%, respectively. The importance of the treatment protocol has been confirmed in a multivariate analysis which demonstrated that the treatment protocol adopted is one of the prognostic factors with an independent value (p = 0.06).

UR - http://www.scopus.com/inward/record.url?scp=0026521881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026521881&partnerID=8YFLogxK

M3 - Article

C2 - 1622873

AN - SCOPUS:0026521881

VL - 3

SP - 71

EP - 74

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 2

ER -